Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)

Inclusion Criteria: * Have an ICD implanted and a history of ventricular tachycardia, ventricular fibrillation, or an appropriate ICD therapy. * Have a left ventricular ejection fraction \<= 0.40 Exclusion Criteria: * Have New York Heart Association (NYHA) Class IV Congestive Heart Failure (CHF) or have decompensated CHF at the time of randomization; * Have unstable angina pectoris or a myocardial infarction within 30 days of randomization; * Have a history of Torsade de Pointes or heart transplantation * Have chronic atrial fibrillation or atrial fibrillation/flutter, that is not adequately rate controlled in the judgment of the Investigator, at screening; * Are currently taking systemic Class I or other Class III antiarrhythmic drugs * Are currently taking systemic drugs that prolong the QT interval * If female, are currently pregnant or breast feeding, or plan to become pregnant during the course of the study